2021
DOI: 10.18103/mra.v9i11.2592
|View full text |Cite
|
Sign up to set email alerts
|

The potential for new and resilient anti-cancer drugs based upon minor groove binders for DNA

Abstract: Anti-infective and anticancer drugs share the serious problem that over time resistance develops to their effects leading to clinical obsolescence. Research at the University of Strathclyde has discovered a platform of anti-infective drugs based upon minor groove binders for DNA that have exceptional resilience to the development of resistance in their target organisms (bacteria, fungi, and parasites). This property is associated with the fact that the Strathclyde minor groove binders (S-MGBs) act at more than… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 23 publications
0
1
0
Order By: Relevance
“…Their favorable cytotoxicity profiles to mammalian cells give them selectivity indices that make them suitable for development as novel drugs. This has enabled extensive in vitro and several in vivo experiments to provide proof of concept for S-MGBs as a novel class of anti-infective agent against bacterial, fungal, viral, and parasitic infections. One of these compounds, MGB-BP-3 (Figure ) has successfully completed Phase IIa clinical trials for the treatment of Clostridioides difficile associated disease (NCT03824795). MGB-BP-3 also has potent (<1 μg/mL) antibacterial activity against methicillin-resistant and methicillin-susceptible Staphylococcus spp., Streptococcus spp., and vancomycin-resistant and vancomycin-susceptible Enterococcus spp .…”
mentioning
confidence: 99%
“…Their favorable cytotoxicity profiles to mammalian cells give them selectivity indices that make them suitable for development as novel drugs. This has enabled extensive in vitro and several in vivo experiments to provide proof of concept for S-MGBs as a novel class of anti-infective agent against bacterial, fungal, viral, and parasitic infections. One of these compounds, MGB-BP-3 (Figure ) has successfully completed Phase IIa clinical trials for the treatment of Clostridioides difficile associated disease (NCT03824795). MGB-BP-3 also has potent (<1 μg/mL) antibacterial activity against methicillin-resistant and methicillin-susceptible Staphylococcus spp., Streptococcus spp., and vancomycin-resistant and vancomycin-susceptible Enterococcus spp .…”
mentioning
confidence: 99%